AI-Powered ASX Trading Signals

Real-time insights. Smarter decisions. Better trades.

🔍 Search Stocks 14 day Free Trial

BCAL DIAGNOSTICS LIMITED (BDX)


AI Coverage Rating: Active

ASX AI Signals has generated 5 signal for BDX during the last 90 days, indicating active trading activity and ongoing AI monitoring

Latest BDX Signals

19/06/2026BUY
10/06/2026SELL
05/05/2026SELL

BDX Share Price

Current Price$0.075
52 Week High$0.135
52 Week Low:$0.052
Trading at (% of 52 Week High) 55.56%


Volume 138
20 Day Avg 954430
Relative Volume 0.0%


Business Overview

BCAL Diagnostics Limited (ASX: BDX) is an Australian company that develops and commercializes medical diagnostic tests. It focuses on improving early detection and management of respiratory diseases through advanced biomarker technology. The company aims to support better patient outcomes with non-invasive, accurate testing solutions.

ASX Sector Overview

Sector:   Pharmaceuticals, Biotechnology & Life Sciences

The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.

Latest AI Recommendation

The BUY signal for BDX at a low price point suggests potential upside, but limited available data and the company's small market presence reduce confidence. Additional fundamental and technical analysis is recommended before committing.

Latest  BCAL DIAGNOSTICS LIMITED(BDX)   News

12 May 2022, 02:29 AM

BCAL Files Foundational Patent Application

New lipid biomarkers central to development of breast cancer diagnostic blood test are coveredPatent application will underpin future global filings securing key features of BCAL’s test SYDNEY, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- Breast cancer screening and diagnostic company BCAL Diagnos

Unlock All ASX AI Signals

Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.

14 Day Free Trial • Cancel Anytime • Founders Price $15/month

Start My Free Trial